LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

96.62 -0.86

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

95.74

Max

97.81

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	13.723 50.102
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 368M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+11.07% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	362M 19B
Iepriekšējā atvēršanas cena	97.48
Iepriekšējā slēgšanas cena	96.62

Ziņu noskaņojums

By Acuity

48%

52%

152 / 344 Rangs Healthcare

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 29. maijs 23:08 UTC

Iegādes, apvienošanās, pārņemšana

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

2026. g. 29. maijs 23:06 UTC

Iegādes, apvienošanās, pārņemšana

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

2026. g. 29. maijs 20:53 UTC

Peļņas

Oil Declines Lift Stocks to Fresh Records -- WSJ

2026. g. 29. maijs 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 20:33 UTC

Tirgus saruna

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

2026. g. 29. maijs 20:11 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 19:47 UTC

Peļņas

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

2026. g. 29. maijs 19:36 UTC

Tirgus saruna

U.S. Natural Gas Futures End Month With Gains -- Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 29. maijs 19:34 UTC

Tirgus saruna

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

2026. g. 29. maijs 19:22 UTC

Tirgus saruna

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

2026. g. 29. maijs 19:05 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

2026. g. 29. maijs 18:19 UTC

Tirgus saruna

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

2026. g. 29. maijs 18:12 UTC

Iegādes, apvienošanās, pārņemšana

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

2026. g. 29. maijs 18:11 UTC

Tirgus saruna

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

2026. g. 29. maijs 18:10 UTC

Tirgus saruna

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

2026. g. 29. maijs 17:55 UTC

Peļņas

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

2026. g. 29. maijs 17:55 UTC

Tirgus saruna

NEAR Protocol Nearly Doubles in May -- Market Talk

2026. g. 29. maijs 17:38 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

2026. g. 29. maijs 17:00 UTC

Peļņas

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 29. maijs 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 29. maijs 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 29. maijs 16:02 UTC

Tirgus saruna

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 29. maijs 15:55 UTC

Tirgus saruna

Cryptocurrencies Appear Detached From Stocks -- Market Talk

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

2026. g. 29. maijs 15:50 UTC

Iegādes, apvienošanās, pārņemšana

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

2026. g. 29. maijs 15:40 UTC

Tirgus saruna

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

2026. g. 29. maijs 15:20 UTC

Tirgus saruna

Canada's Economy Not Looking All That Bright -- Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.07% augšup

Prognoze 12 mēnešiem

Vidējais 108.29 USD 11.07%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

152 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation